Bio Plus Co., Ltd
099430.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$236.32B
Close$
Share Statistics
| Market cap | $236.32 Billion |
|---|---|
| Enterprise Value | $281.79 Billion |
| Dividend Yield | $50.00 (1.30%) |
| Earnings per Share | $253 |
| Beta | 0.56 |
| Outstanding Shares | 61,290,000 |
Return
| Return on Equity | 7.76% |
|---|---|
| Return on Assets | 4.67% |
| Return on Invested Capital | 8.56% |
Valuation & Multiples
| P/E Ratio | 16.86 |
|---|---|
| PEG | -246.56 |
| Price to Sales | 2.25 |
| Price to Book Ratio | 1.12 |
| Enterprise Value to Revenue | 2.84 |
| Enterprise Value to EBIT | 14.66 |
| Enterprise Value to Net Income | 20 |
| Total Debt to Enterprise | 0.23 |
| Debt to Equity | 0.37 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$28.23 B
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$31.02 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bio Plus Co., Ltd
187 employees
CEO: Hyun-Kyu Jung Based in Seongnam-si, South Korea, Bio Plus Co., Ltd, established in 2003, is dedicated to the investigation, formulation, production, and commercialization of bio-based items. The company’s diverse offerings include a variety of dermal ...